Earnings Call Intelligence Subscribe
Home › Call Sheets › ABBV › Q1'26
Call sheet · Q1'26

AbbVie (ABBV)

Q1'26 earnings call · held April 29, 2026 · compared with the Q4'25 call · management-credibility review
9/12
Disclosure score
1 medium, 5 low flags
Financial quality
Bottom line
The sleeper story is the combination platform doubling IBD efficacy - while everyone focuses on oral competition threats, AbbVie is building next-generation therapies that could reset treatment standards by 2028. The obvious headline is continued robust growth, but the real story is they're quietly managing a transition from pricing tailwinds to headwinds while stopping quantification of their biggest known headwind (HUMIRA erosion). The binding constraint isn't demand or competition - it's manufacturing execution, with $1.8B in new facility commitments and regulatory delays on key launches. Most revealing quote was Scott's warning about 'high single-digit pricing headwinds for remainder of the year' after Q1 appeared benign. My view changes if quarterly FCF disclosure doesn't return or if VYALEV misses the $1B target, which would signal execution issues in their highest-growth franchises.

The 30-second version

  • SLEEPER STORY: Combo platform is doubling efficacy rates while everyone obsesses over oral competition
  • Pricing held flat in Q1 despite guidance for low single-digit declines - but it's a timing mirage
  • Management quietly stopped quantifying HUMIRA erosion impact while claiming 'in line with expectations'

What changed this quarter

MetricQ4'25Q1'26Change
Total Revenue$16.6B (+10.0% YoY)$15.0B (+12.4% YoY)+240bps acceleration despite lower base
Adjusted EPS$2.71 (+8% above guide)$2.65 (+7% above guide)Beat consistency maintained
Skyrizi Revenue$5.0B (+31.9% op)$4.5B (+29.2% op)-270bps deceleration but beat expectations
Rinvoq Revenue$2.4B (+28.6% op)$2.1B (+20.2% op)-840bps deceleration
Immunology Total$8.6B$7.3B$1B absolute growth maintained
Neuroscience Revenue$2.9B (+17.3% op)$2.9B (+24.3% op)+700bps acceleration
VYALEV Revenue$183M (+33% sequential)$201M (+10% sequential)Sequential momentum slowing but hitting $1B guide
Vraylar Revenue$1.0B$905MSequential decline but +18.4% YoY
HUMIRA Revenue$1.2B (-26.1% op)$688M (-40.3% op)-1420bps acceleration in decline
Adjusted Operating Margin38.3% (inc 7.6% IPR&D hit)40.8% (inc 5% IPR&D hit)+250bps improvement

Accountability tracked

8 new promises made4 narrative shifts flagged6 prior promises scored
Inside the full report
The complete write-up covers the full promise ledger with kept/missed calls, disclosure-quality scoring, the metrics-vanished check, verification items, and the questions to ask next quarter.
Read the full ABBV Q1'26 report Subscribe
About Research ↗Call SheetsCredibility IndexMissed PromisesScreens13F BooksData & InstitutionalPrivacyTermsSubscribe
This is a free preview. The full write-up and promise ledger are published to subscribers on Substack.
Scores, kept-promise rates, and flags on this site reflect the author's opinion, applying a stated methodology to statements management made on public earnings calls. Informational and educational purposes only - not investment advice, a recommendation, or an offer to buy or sell any security. Sources believed reliable but not guaranteed; the author may hold positions in the securities discussed.

Follow what management promises next

Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.

Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.